ArticleJTO clinical and research reports2023

Survival Benefit of Perioperative Systemic Chemotherapy for Patients With N0 to N1 NSCLC Having Synchronous Brain Metastasis.

Yeshwanth R Vedire et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.